Seeking Redevelopment Opportunities for the Treatment of Rare or Orphan Diseases

Healx, an AI-powered, patient-inspired, biotech company based in Cambridge (UK), is seeking drug redevelopment opportunities from academics, clinicians or recent university spinouts in the area of Rare Disease. Healx will collaborate with the asset holders to quickly turn their research into approved treatments that benefit the rare disease community.

Approaches of Interest

- Open to rare or orphan diseases (prevalence <5/10,000) with current unmet medical needs, with a particular interest in rare renal, inflammatory, neuromuscular, bone and ocular conditions
- Ideally, the rare or orphan indication has well-characterised natural history, established clinical trial endpoints and/or biomarkers and, if applicable, sufficient patients willing and able to participate in clinical trials
- Healx is open to most modalities, with a particular interest in small molecules, as well as new platform technologies (e.g. novel delivery systems) that are (nearly) market-ready and can improve patient outcomes and create commercially viable drug redevelopment

Stage of Development

- Healx is open to opportunities at the basic to clinical stage, mostly favouring the late preclinical and clinical stages
- Preclinically-validated in models (in vitro and/or in vivo) that are representative of the disease of interest are preferred

Ideal Candidate Profile

- Drug redevelopment (modifying an approved drug, nutraceutical or human-safe compound for the treatment of a new indication) or late-stage new chemical entity (NCE) candidates, or new technology platforms to aid drug redevelopment
- Patent protection available or already prosecuted (composition of matter, method of use and/or formulation patents)
- For opportunities redeveloping approved drugs or nutraceuticals: there needs to be a chance to create or enhance both patient impact and commercial viability through reformulation, combination or other modifications

Out of Scope

- Gene therapy, biologics and cell therapy approaches are not of interest
- For rare oncology, Healx is not currently looking for opportunities in acute metastatic cancers with multiple genetic origins but they are open to opportunities related to single gene-derived benign tumour types, e.g. neurofibromatosis

Opportunity for Collaboration and Submission Information

- Healx is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include in-licensing clinic-ready assets for clinical development, option agreements with research funding and co-development for preclinical assets
- Submission of one page, 200-300 word briefs or completion of the optional submission form are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information